Logo Informatori.Info

 

 

mar23

Vitae Pharma's Psoriasis Drug Succeeds in Mid-stage Study


Drug developer Vitae Pharmaceuticals Inc said its experimental psoriasis drug significantly reduced the skin condition in patients from a mid-stage trial, sending its shares up 70 percent in after-hours trading.

 

Patients taking a 350 mg dose of the drug, VTP-43742, showed a 24 percent reduction, while patients who took the 700 mg dose showed a 30 percent reduction compared to placebo.

Psoriasis affects about 7.5 million people in the United States.

There are currently a range of treatments to improve symptoms but no cure. The autoimmune disease market is currently dominated by injectable therapies.

VTP-43742, which is a once-a-day oral drug, has the potential to treat other disorders such as rheumatoid arthritis, multiple sclerosis and inflammatory bowel diseases, the company said.

Psoriasis has been targeted as a promising treatment area by a number of drugmakers, including Novartis AG, which recently launched a product called Cosentyx (secukinumab) for the condition.

This month, U.S. drugmaker AbbVie Inc bought marketing rights to a promising experimental psoriasis treatment from Germany's Boehringer Ingelheim for an initial upfront payment of $595 million.

23/03/2016 - Categoria: Farmaci - Da: Sh@wn - 402 letture

 

  Commenti

Nessun Commento.

Il tuo Nome
Email
Website
Titolo
Commento
Immagine CAPTCHA
Inserisci il codice

RITORNA ALLA PAGINA PRECEDENTE

Cerca un articolo

Argomenti
Skip Navigation Links.

AIFA

AIISF

Articoli Scientifici

ASL

Associazioni-Sindacati

Auto Aziendale

Aziende Farmaceutiche

British Medical Journal

Codice Strada

Congressi

Contravvenzioni

Dispositivi Medici

Enasarco

Eventi

Eventi ECM

Farmaci

Farmacie

Farmindustria

Faschim

Federaisf

Fonchim

Informatori

Jama

Lancet

New England

Parafarmacie

RSU Aziende

Sanita'

SLF Cobas

);